Immuron Limited (AU:IMC) has released an update. Immuron Limited’s CEO, Steven Lydeamore, will participate in a fireside chat at the Maxim Virtual Healthcare Conference, highlighting the company’s innovative work in
Immuron Limited (AU:IMC) has released an update. Immuron Limited’s CEO, Steven Lydeamore, will participate in a fireside chat at the Maxim Virtual Healthcare Conference, highlighting the company’s innovative work in
Immuron Limited (AU:IMC) has released an update. Immuron Limited’s CEO, Steven Lydeamore, will participate in a fireside chat at the Maxim Virtual Healthcare Conference, showcasing the company’s innovative biopharmaceutical advancements.
Immuron Limited announced continued strong sales growth of Travelan, an over-the-counter immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal tract. Flavio Palumbo, Chief Commercial
Immuron Limited (AU:IMC) has released an update. Immuron Limited reports robust sales growth for its gastrointestinal supplement Travelan, with a 13% increase globally in the September 2024 quarter, led by
Immuron Limited (AU:IMC) has released an update. Immuron Limited has announced a new application for the quotation of securities, with 1,147,083 ordinary fully paid shares to be quoted on the